Concord Biotech Ltd

Concord Biotech Limited — Trading Window closed from Oct 01, 2026 till the expiry of 48 hours after the declaration of the Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Postal ballot resolutions

• Increase authorised share capital to ₹22 crore (22,00,00,000 shares of ₹1 each).
• Alter MOA Clause V to reflect new authorised capital; Ordinary Resolution.
• Capitalize ₹10,46,16,204 from securities premium for 1:1 bonus shares.
• Bonus shares to be fully paid and rank pari passu.
• Record date to be fixed by the Board.

Bonus details and capital structure

• Type of security and face value: Equity shares of Rs 1 each.
• Bonus ratio: 1:1 for every existing share.
• Source of bonus: capitalization of share premium available as on March 31, 2026.
• Total bonus shares: 10,46,16,204 equity shares to be issued.
• Pre- and post-bonus share capital: pre-bonus paid-up Rs 10,46,16,204; post-bonus Rs 20,92,32,408.
• Authorised capital: increased from Rs 11,00,00,000 to Rs 22,00,00,000.
• Record date: to be decided by the Board.
• Estimated credit/dispatch: within 2 months from board approval, by November 22, 2026.
• Audited: Yes; figures based on March 31, 2026 balance sheet.
• Subject to shareholder approval; record date to be fixed by Board.
• Authorized capital increase requires shareholder approval.

Meeting Details

• Date: September 23, 2026

Key Agenda Items

• Consider proposal to declare bonus equity shares to existing shareholders, subject to shareholders' approval

Other Notes

• Trading window closed for designated persons until 48 hours after board outcome; opens September 26, 2026

USFDA inspection outcome

• USFDA inspection at Unit II Valthera, Ahmedabad, concluded on September 18, 2026 with one minor procedural observation.
• Observation is procedural and not related to GMP; a comprehensive response will be submitted within the timeline.
• No material impact on operations or current supplies expected.

Meeting Details

• Date & time: 23 September 2026, 12:30 PM.
• Nature: Group meeting with investors/analysts.
• Organised by: JP Morgan Healthcare Trip.
• Place: Ahmedabad.

Participants

• Company officials to participate in the group meeting.

Purpose

• Discussions based on publicly available information; UPSI not discussed.

Meeting Details

• Date and time: 26 August 2026, 01:00–03:00 IST.
• Type and mode: group meeting, physical in Ahmedabad.
• Organizer: Phillip Capital PCG.
• Key participants: Company Secretary & Compliance Officer.
• Purpose: investor conference; discussions based on public information.

Financial Performance

• Q1 FY27 revenue was INR 257 crores, up 26.2% YoY.
• API revenue INR 219 crores, up 42% YoY.
• Formulation revenue INR 39 crores, down 23%.
• Gross margin 78.9%, up 100 bps YoY.
• EBITDA INR 82 crores, up 34%; margin 32%.
• PAT INR 58 crores, up 31%; margin 22.4%.
• Export revenue grew 46% YoY; domestic revenue grew 12%.
• Net debt is zero; cash and cash equivalents exceed INR 442 crores.
• Capex for the quarter about INR 9.5 crores.
• Injectables facility ramp-up supports revenue growth and margin expansion.
• ANDA approvals: US FDA for mycophenolate mofetil and Tofacitinib tablets.

Operations and Product Updates

• Stellon Biotech launched; front-end US distribution for formulation products.
• Injectables facility commercialized; stability batches in progress; filings underway.
• Unit utilizations: Unit 1 ~80%, Unit 3 ~55%, Unit 2 ~25%.
• Fusidic acid launched FY26; expected to contribute to revenue.
• 8–10 products in pipeline; 2–3 oncology; majority anti-infectives/antifungals.
• Domestic formulations grew double-digit; Middle East contribution declined this quarter.

Regulatory and Approvals

• ANVISA Brazil inspection for Limbasi; PPB Kenya; NDA Uganda for Unit 2 Valthera completed.
• US FDA ANDA approvals for mycophenolate mofetil and Tofacitinib tablets.
• EcoVadis silver medal for sustainability; top 15% globally.

Growth Outlook

• FY27 growth expected to exceed historical rate.
• 40% EBITDA margin target contingent on injectable and Stellon ramp.
• Roadmap to INR 3,000 crores revenue in 5–6 years.
• API capex trigger at Unit 3 utilization around 80–85%.
• Limbasi brownfield expansion option if needed.

Capital Allocation

• Net cash position; zero debt; cash over INR 442 crores.
• Dividend payout ongoing; exploring organic and inorganic growth.

Meeting Details

• Date and time: August 3, 2026, 3:30 PM IST.
• Type and mode: earnings call; virtual conference.
• Event/organiser: Earnings Call for Q1 FY27 results.
• Purpose: discuss unaudited standalone and consolidated Q1 FY27 results.

Participants

• Key company participants: Company Secretary and Compliance Officer.

Additional Notes

• Audio recording of the earnings call available on the company website.